Page 1 | Search Results | Cancer Discovery | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Pan-Cancer Efficacy of Vemurafenib in BRAF^V600-Mutant Non-Melanoma Cancers

Vivek Subbiah, Igor Puzanov, Jean-Yves Blay, Ian Chau, A. Craig Lockhart, Noopur S. Raje, Juergen Wolf, José Baselga, Funda Meric-Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman

Cancer Discov (2020) 10 (5): 657–663.

https://doi.org/10.1158/2159-8290.CD-19-1265

Published: 01 May 2020

View article titled, Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Includes: Supplementary data

Journal Articles

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Cancer Discov (2020) 10 (3): 440–459.

https://doi.org/10.1158/2159-8290.CD-19-0116

Published: 03 March 2020

View article titled, Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Includes: Supplementary data

Journal Articles

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Cancer Discov (2020) 10 (2): 198–213.

https://doi.org/10.1158/2159-8290.CD-19-0966

Published: 05 February 2020

View article titled, Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Includes: Supplementary data

Journal Articles

Accelerating Discovery of Functional Mutant Alleles in Cancer

Cancer Discov (2018) 8 (2): 174–183.

https://doi.org/10.1158/2159-8290.CD-17-0321

Published: 04 February 2018

View article titled, Accelerating Discovery of Functional Mutant Alleles in Cancer

Includes: Supplementary data

Journal Articles

AACR Project GENIE: Powering Precision Medicine through an International Consortium

The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, Fabrice André, Monica Arnedos, Alexander S. Baras, José Baselga, Philippe L. Bedard, Michael F. Berger, Mariska Bierkens, Fabien Calvo, Ethan Cerami, Debyani Chakravarty, Kristen K. Dang, Nancy E. Davidson, Catherine Del Vecchio Fitz, Semih Dogan, Raymond N. DuBois, Matthew D. Ducar, P. Andrew Futreal, Jianjiong Gao, Francisco Garcia, Stu Gardos, Christopher D. Gocke, Benjamin E. Gross, Justin Guinney, Zachary J. Heins, Stephanie Hintzen, Hugo Horlings, Jan Hudeček, David M. Hyman, Suzanne Kamel-Reid, Cyriac Kandoth, Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefebvre, Michele L. LeNoue-Newton, Eva M. Lepisto, Mia A. Levy, Neal I. Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E. MacConaill, Ian Maurer, David S. Maxwell, Gerrit A. Meijer, Funda Meric-Bernstam, Christine M. Micheel, Clinton Miller, Gordon Mills, Nathanael D. Moore, Petra M. Nederlof, Larsson Omberg, John A. Orechia, Ben Ho Park, Trevor J. Pugh, Brendan Reardon, Barrett J. Rollins, Mark J. Routbort, Charles L. Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna R Mills Shaw, Priyanka Shivdasani, Lillian L. Siu, David B. Solit, Gabe S. Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie H. Stickle, Thomas P. Stricker, Shawn M. Sweeney, Barry S. Taylor, Jelle J. ten Hoeve, Stacy B. Thomas, Eliezer M. Van Allen, Laura J. Van 'T Veer, Tony van de Velde, Harm van Tinteren, Victor E. Velculescu, Carl Virtanen, Emile E. Voest, Lucy L. Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas V. Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang

Cancer Discov (2017) 7 (8): 818–831.

https://doi.org/10.1158/2159-8290.CD-17-0151

Published: 01 August 2017

View article titled, AACR Project GENIE: Powering Precision Medicine through an International Consortium

Includes: Supplementary data

Journal Articles

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Dejan Juric, Ian Krop, Ramesh K. Ramanathan, Timothy R. Wilson, Joseph A. Ware, Sandra M. Sanabria Bohorquez, Heidi M. Savage, Deepak Sampath, Laurent Salphati, Ray S. Lin, Huan Jin, Hema Parmar, Jerry Y. Hsu, Daniel D. Von Hoff, José Baselga

Cancer Discov (2017) 7 (7): 704–715.

https://doi.org/10.1158/2159-8290.CD-16-1080

Published: 05 July 2017

View article titled, Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Cancer Discov (2017) 7 (6): 596–609.

https://doi.org/10.1158/2159-8290.CD-16-1337

Published: 01 June 2017

View article titled, Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Includes: Supplementary data

Journal Articles

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists

Cancer Discov (2017) 7 (3): 277–287.

https://doi.org/10.1158/2159-8290.CD-15-1523

Published: 05 March 2017

View article titled, Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists

Includes: Supplementary data

Journal Articles

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Cancer Discov (2017) 7 (1): 102–113.

https://doi.org/10.1158/2159-8290.CD-16-0512

Published: 05 January 2017

View article titled, A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Includes: Supplementary data

Journal Articles

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

Xiuning Le, Rajee Antony, Pedram Razavi, Daniel J. Treacy, Flora Luo, Mahmoud Ghandi, Pau Castel, Maurizio Scaltriti, José Baselga, Levi A. Garraway

Cancer Discov (2016) 6 (10): 1134–1147.

https://doi.org/10.1158/2159-8290.CD-16-0305

Published: 02 October 2016

View article titled, Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

Includes: Supplementary data

Journal Articles

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Cancer Discov (2016) 6 (2): 154–165.

https://doi.org/10.1158/2159-8290.CD-15-0913

Published: 04 February 2016

View article titled, Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Includes: Supplementary data

Journal Articles

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

Cancer Discov (2015) 5 (11): 1164–1177.

https://doi.org/10.1158/2159-8290.CD-15-0369

Published: 01 November 2015

View article titled, Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

Includes: Supplementary data

Journal Articles

Prospective Blinded Study of BRAF^V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

Cancer Discov (2015) 5 (1): 64–71.

https://doi.org/10.1158/2159-8290.CD-14-0742

Published: 11 January 2015

View article titled, Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

Includes: Supplementary data

Journal Articles

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling

Marie Will, Alice Can Ran Qin, Weiyi Toy, Zhan Yao, Vanessa Rodrik-Outmezguine, Claudia Schneider, Xiaodong Huang, Prashant Monian, Xuejun Jiang, Elisa de Stanchina, José Baselga, Ningshu Liu, Sarat Chandarlapaty, Neal Rosen

Cancer Discov (2014) 4 (3): 334–347.

https://doi.org/10.1158/2159-8290.CD-13-0611

Published: 03 March 2014

View article titled, Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling

Includes: Supplementary data

Journal Articles

Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2^V659E Mutation

Violeta Serra, Ana Vivancos, Xose S. Puente, Enriqueta Felip, Daniel Silberschmidt, Ginevra Caratù, Josep-Lluís Parra, Leticia De Mattos-Arruda, Judit Grueso, Javier Hernández-Losa, Joaquín Arribas, Ludmila Prudkin, Paolo Nuciforo, Maurizio Scaltriti, Joan Seoane, José Baselga

Cancer Discov (2013) 3 (11): 1238–1244.

https://doi.org/10.1158/2159-8290.CD-13-0132

Published: 06 November 2013

View article titled, Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation

Includes: Supplementary data

Journal Articles

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Cancer Discov (2012) 2 (11): 1036–1047.

https://doi.org/10.1158/2159-8290.CD-11-0348

Published: 11 November 2012

View article titled, PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Includes: Supplementary data

Journal Articles

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley, Gerburg M. Wulf

Cancer Discov (2012) 2 (11): 1048–1063.

https://doi.org/10.1158/2159-8290.CD-11-0336

Published: 11 November 2012

View article titled, Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Includes: Supplementary data

Journal Articles

Whole-Genome Sequencing and Cancer Therapy: Is Too Much Ever Enough?

Levi A. Garraway, José Baselga

Cancer Discov (2012) 2 (9): 766–768.

https://doi.org/10.1158/2159-8290.CD-12-0359

Published: 10 September 2012

View article titled, Whole-Genome Sequencing and Cancer Therapy: Is Too Much Ever Enough?

Journal Articles

Cancer Discovery at One Year: The Editors' Interim Analysis

Lewis C. Cantley, PhD, José Baselga, MD, PhD

Cancer Discov (2012) 2 (1): vi.

https://doi.org/10.1158/2159-8290.CD-11-0327

Published: 12 January 2012

View article titled, Cancer Discovery at One Year: The Editors' Interim Analysis

Journal Articles

BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors

Cancer Discov (2011) 1 (4): 352–365.

https://doi.org/10.1158/2159-8290.CD-11-0106

Published: 14 September 2011

View article titled, BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors

Includes: Multimedia, Supplementary data

NARROW

Pan-Cancer Efficacy of Vemurafenib in BRAF^V600-Mutant Non-Melanoma Cancers

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Accelerating Discovery of Functional Mutant Alleles in Cancer

AACR Project GENIE: Powering Precision Medicine through an International Consortium

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

Prospective Blinded Study of BRAF^V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling

Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2^V659E Mutation

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

Whole-Genome Sequencing and Cancer Therapy: Is Too Much Ever Enough?

Cancer Discovery at One Year: The Editors' Interim Analysis

BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only